News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News Novartis to buy ophthalmology firm Encore Vision Swiss pharma buys treatment for common age-related vision problem.
News Novartis/Ophthotech eye combo fails in phase 3 Lucentis and pegpleranib combination misses goal in wet AMD.
News Regeneron to develop long release Eylea successor Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
News Shire launches potential blockbuster dry eye drug in US Xiidra could be ophthalmology blockbuster.
Oncology CAR-T therapies: Faster, better, cheaper In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
